Latest Quarterly Report
Filed: 2026-01-13
Key Insights
- The company's retained earnings and additional paid-in capital have been steadily increasing over the past few years, indicating potential financial stability and growth.
- The majority shareholder and president has entered into various licensing agreements and research and development arrangements, which could provide additional revenue streams and growth opportunities.
- The company has received funding for clinical trials, research, and operational support from related parties, potentially helping to finance its ongoing operations and development efforts.